cephalexin has been researched along with acyclovir in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Avdeef, A; Tam, KY | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Balasubramanian, S; Giannadaki, E; Greenstein, AJ; Manousos, ON; Mouzas, IA; Sachar, DB | 1 |
| de Vrueh, RL; Lee, CP; Smith, PL | 1 |
| Amidon, GL; Chu, X; Fleisher, D; Komorowski, TE; Landowski, CP; Sun, D; Wallsten, R | 1 |
| Anderle, P; Chin-Hong, P; Guglielmo, BJ; Lin, ET; Phan, DD; Sadee, W | 1 |
| Bado, A; Beaufils, B; Buyse, M; Farinotti, R; Hindlet, P; Radeva, G; Walker, F | 1 |
| Bayart, C; Brandling-Bennett, H; Yang, S | 1 |
2 review(s) available for cephalexin and acyclovir
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for cephalexin and acyclovir
| Article | Year |
|---|---|
Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor.
Topics: Acyclovir; Administration, Oral; Anti-Bacterial Agents; Antiviral Agents; Carrier Proteins; Cephalexin; Drug Interactions; Female; Humans; Male; Peptide Transporter 1; Symporters; Valacyclovir; Valine | 2003 |
14 other study(ies) available for cephalexin and acyclovir
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Management of varicella infection during the course of inflammatory bowel disease.
Topics: Acyclovir; Adult; Anti-Inflammatory Agents; Antiviral Agents; Azathioprine; Cause of Death; Cephalexin; Cephalosporins; Chickenpox; Child; Colectomy; Colitis, Ulcerative; Crohn Disease; Female; Glucocorticoids; Humans; Immunocompromised Host; Immunosuppressive Agents; Inflammatory Bowel Diseases; Injections, Intravenous; Male; Megacolon, Toxic; Methylprednisolone; Prednisone; Rectum; Remission Induction; Treatment Outcome | 1997 |
Transport of L-valine-acyclovir via the oligopeptide transporter in the human intestinal cell line, Caco-2.
Topics: Acyclovir; Antiviral Agents; Biological Transport; Caco-2 Cells; Carrier Proteins; Cephalexin; Dose-Response Relationship, Drug; Drug Stability; Humans; Hydrogen-Ion Concentration; Intestinal Mucosa; Valine | 1998 |
Drug inhibition of Gly-Sar uptake and hPepT1 localization using hPepT1-GFP fusion protein.
Topics: Acyclovir; Blotting, Western; Caco-2 Cells; Carrier Proteins; Cell Membrane; Cephalexin; Depression, Chemical; Dipeptides; Green Fluorescent Proteins; HeLa Cells; Humans; Luminescent Proteins; Microscopy, Confocal; Peptide Transporter 1; Recombinant Fusion Proteins; Subcellular Fractions; Symporters; Transfection; Valacyclovir; Valine | 2001 |
Regulation of the oligopeptide transporter, PEPT-1, in DSS-induced rat colitis.
Topics: Acyclovir; Animals; Anti-Bacterial Agents; Antiviral Agents; Biological Availability; Cephalexin; Colitis; Immunohistochemistry; Intestinal Mucosa; Male; Peptide Transporter 1; Rats; Rats, Wistar; RNA, Messenger; Symporters; Valacyclovir; Valine | 2007 |
An atypical presentation of herpes simplex virus infection in Harlequin ichthyosis.
Topics: Acyclovir; Anti-Bacterial Agents; Antiviral Agents; Cephalexin; Female; Herpes Simplex; Herpesvirus 1, Human; Humans; Ichthyosis, Lamellar; Infant; Valacyclovir; Valine | 2018 |